J Mora1, S Perez-Jaume2, O Cruz2. 1. Department of Pediatric Oncology and Hematology, Hospital Sant Joan de Déu, Passeig de Sant Joan de Deu, 2, Esplugues de Llobregat, 08950, Barcelona, Spain. jmora@sjdhospitalbarcelona.org. 2. Department of Pediatric Oncology and Hematology, Hospital Sant Joan de Déu, Passeig de Sant Joan de Deu, 2, Esplugues de Llobregat, 08950, Barcelona, Spain.
Abstract
BACKGROUND: Previously we described the outcome of children with spinal cord astrocytoma treated with irinotecan and cisplatin (I/C). We here report the review of the initial institutional experience using this combination for children with low-grade glioma (LGG). PROCEDURE: I/C chemotherapy consisted of weekly cisplatin (30 mg/m2) and irinotecan (50-65 mg/m2) for a total maximum of 16 doses, administered in an outpatient basis. RESULTS: Between November 2002 and December 2009, 46 children (median age 6.3 years; range 0.3-17.7) with glioma were treated. We here report the cohort of 31 patients with LGG. Patients received a median of 16 cycles of I/C (range 8-16). The overall objective response [complete response (CR) + partial response (PR)] and disease control (CR + PR + stable disease) rates to I/C treatment were 6.5% [95% confidence interval (CI), 0.8-21.4%] and 93.5% (95% CI 78.6-99.2%), respectively. Disease control persisted for a median of 65 months. Toxicity was predominantly myelosuppression only seen in heavily pretreated patients. Survival analysis shows 5-year event-free survival (EFS) of 54% and 5-year overall survival (OS) of 80%. CONCLUSION: I/C chemotherapy produced disease control and clinical improvement in a majority of children with low-grade glioma, with manageable toxicity.
BACKGROUND: Previously we described the outcome of children with spinal cord astrocytoma treated with irinotecan and cisplatin (I/C). We here report the review of the initial institutional experience using this combination for children with low-grade glioma (LGG). PROCEDURE: I/C chemotherapy consisted of weekly cisplatin (30 mg/m2) and irinotecan (50-65 mg/m2) for a total maximum of 16 doses, administered in an outpatient basis. RESULTS: Between November 2002 and December 2009, 46 children (median age 6.3 years; range 0.3-17.7) with glioma were treated. We here report the cohort of 31 patients with LGG. Patients received a median of 16 cycles of I/C (range 8-16). The overall objective response [complete response (CR) + partial response (PR)] and disease control (CR + PR + stable disease) rates to I/C treatment were 6.5% [95% confidence interval (CI), 0.8-21.4%] and 93.5% (95% CI 78.6-99.2%), respectively. Disease control persisted for a median of 65 months. Toxicity was predominantly myelosuppression only seen in heavily pretreated patients. Survival analysis shows 5-year event-free survival (EFS) of 54% and 5-year overall survival (OS) of 80%. CONCLUSION: I/C chemotherapy produced disease control and clinical improvement in a majority of children with low-grade glioma, with manageable toxicity.
Authors: Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Katrin Scheinemann; Ute Bartels; Elena Tsangaris; Cynthia Hawkins; Annie Huang; Peter Dirks; Iris Fried; Eric Bouffet; Uri Tabori Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Alvaro Lassaletta; Katrin Scheinemann; Shayna M Zelcer; Juliette Hukin; Beverley A Wilson; Nada Jabado; Anne Sophie Carret; Lucie Lafay-Cousin; Valerie Larouche; Cynthia E Hawkins; Gregory Russell Pond; Ken Poskitt; Daniel Keene; Donna L Johnston; David D Eisenstat; Rahul Krishnatry; Matthew Mistry; Anthony Arnoldo; Vijay Ramaswamy; Annie Huang; Ute Bartels; Uri Tabori; Eric Bouffet Journal: J Clin Oncol Date: 2016-10-10 Impact factor: 44.544
Authors: Joann L Ater; Caihong Xia; Claire M Mazewski; Timothy N Booth; David R Freyer; Roger J Packer; Richard Sposto; Gilbert Vezina; Ian F Pollack Journal: Cancer Date: 2016-04-08 Impact factor: 6.860
Authors: V Doireau; J Grill; M Zerah; A Lellouch-Tubiana; D Couanet; P Chastagner; J C Marchal; Y Grignon; Z Chouffai; C Kalifa Journal: Br J Cancer Date: 1999-11 Impact factor: 7.640